Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
News & Media
Home
>
News & Media
>
Media
Media
Media
Filter by Year:
2025
2024
2023
5-Dec-2017
Neuren Pharmaceuticals gets green light for a patent in the U.S.
29-Jun-2017
Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials
22-Mar-2017
Neuren Pharmaceuticals drug shows promise in treating Rett syndrome
19-Mar-2017
Neuren Pharmaceuticals granted ASX trading halt pending trial update
Previous
1
2
3